Mark Schneyer Sells 14,292 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 14,292 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $29.22, for a total value of $417,612.24. Following the transaction, the executive vice president directly owned 67,828 shares of the company’s stock, valued at $1,981,934.16. The trade was a 17.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Trading Up 2.7%

Shares of NASDAQ ACAD traded up $0.76 during trading on Friday, reaching $29.21. The company had a trading volume of 1,782,652 shares, compared to its average volume of 1,684,264. ACADIA Pharmaceuticals Inc. has a twelve month low of $19.69 and a twelve month high of $29.48. The stock has a 50-day moving average price of $24.24 and a two-hundred day moving average price of $23.23. The stock has a market capitalization of $5.00 billion, a PE ratio of 13.16, a price-to-earnings-growth ratio of 19.47 and a beta of 0.81.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The business’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 earnings per share. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.4 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday. Citigroup reaffirmed a “market outperform” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday. Canaccord Genuity Group increased their price target on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Finally, BMO Capital Markets lifted their price objective on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, July 21st. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.44.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of large investors have recently bought and sold shares of ACAD. Farther Finance Advisors LLC increased its holdings in shares of ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at $26,000. Transamerica Financial Advisors LLC grew its position in ACADIA Pharmaceuticals by 304.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,005 shares during the period. Federated Hermes Inc. grew its position in ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,185 shares during the period. Finally, Leonteq Securities AG purchased a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at about $52,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.